36 related articles for article (PubMed ID: 29661776)
1. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model.
Ma Q; Wang C; Jones D; Quintanilla KE; Li D; Wang Y; Wieder ED; Clise-Dwyer K; Alatrash G; Mj Y; Munsell MF; Lu S; Qazilbash MH; Molldrem JJ
Cytotherapy; 2010 Dec; 12(8):1056-62. PubMed ID: 20735170
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells.
Chawla A; Alatrash G; Philips AV; Qiao N; Sukhumalchandra P; Kerros C; Diaconu I; Gall V; Neal S; Peters HL; Clise-Dwyer K; Molldrem JJ; Mittendorf EA
Cancer Immunol Immunother; 2016 Jun; 65(6):741-51. PubMed ID: 27129972
[TBL] [Abstract][Full Text] [Related]
3. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.
Molldrem JJ; Lee PP; Kant S; Wieder E; Jiang W; Lu S; Wang C; Davis MM
J Clin Invest; 2003 Mar; 111(5):639-47. PubMed ID: 12618518
[TBL] [Abstract][Full Text] [Related]
4. Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma.
Yang J; Cao Y; Hong S; Li H; Qian J; Kwak LW; Yi Q
Clin Cancer Res; 2009 Feb; 15(3):951-9. PubMed ID: 19188166
[TBL] [Abstract][Full Text] [Related]
5. Metabolic Features of Multiple Myeloma.
El Arfani C; De Veirman K; Maes K; De Bruyne E; Menu E
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29662010
[TBL] [Abstract][Full Text] [Related]
6. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
7. Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses.
Vermeulen R; Saberi Hosnijeh F; Bodinier B; Portengen L; Liquet B; Garrido-Manriquez J; Lokhorst H; Bergdahl IA; Kyrtopoulos SA; Johansson AS; Georgiadis P; Melin B; Palli D; Krogh V; Panico S; Sacerdote C; Tumino R; Vineis P; Castagné R; Chadeau-Hyam M; ; Botsivali M; Chatziioannou A; Valavanis I; Kleinjans JCS; de Kok TMCM; Keun HC; Athersuch TJ; Kelly R; Lenner P; Hallmans G; Stephanou EG; Myridakis A; Kogevinas M; Fazzo L; De Santis M; Comba P; Bendinelli B; Kiviranta H; Rantakokko P; Airaksinen R; Ruokojarvi P; Gilthorpe M; Fleming S; Fleming T; Tu YK; Lundh T; Chien KL; Chen WJ; Lee WC; Kate Hsiao C; Kuo PH; Hung H; Liao SF
Int J Cancer; 2018 Sep; 143(6):1335-1347. PubMed ID: 29667176
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory effects of CD38-targeting antibodies.
van de Donk NWCJ
Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
Garfall AL; Stadtmauer EA; Hwang WT; Lacey SF; Melenhorst JJ; Krevvata M; Carroll MP; Matsui WH; Wang Q; Dhodapkar MV; Dhodapkar K; Das R; Vogl DT; Weiss BM; Cohen AD; Mangan PA; Ayers EC; Nunez-Cruz S; Kulikovskaya I; Davis MM; Lamontagne A; Dengel K; Kerr ND; Young RM; Siegel DL; Levine BL; Milone MC; Maus MV; June CH
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669947
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy.
Galli M; Chatterjee M; Grasso M; Specchia G; Magen H; Einsele H; Celeghini I; Barbieri P; Paoletti D; Pace S; Sanderson RD; Rambaldi A; Nagler A
Haematologica; 2018 Oct; 103(10):e469-e472. PubMed ID: 29700168
[No Abstract] [Full Text] [Related]
11. MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy.
Samo AA; Li J; Zhou M; Sun Y; Yang Y; Zhang Y; Li J; van Duin M; Lu X; Fan X
Genes Chromosomes Cancer; 2018 Aug; 57(8):420-429. PubMed ID: 29696703
[TBL] [Abstract][Full Text] [Related]
12. Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes.
Padron E; Ball MC; Teer JK; Painter JS; Yoder SJ; Zhang C; Zhang L; Moscinski LC; Rollison DE; Gore SD; Bejar R; Walter MJ; Sekeres MA; Komrokji RS; Epling-Burnette PK
Blood; 2018 May; 131(21):2402-2405. PubMed ID: 29661788
[No Abstract] [Full Text] [Related]
13. Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes.
Alatrash G; Qiao N; Zhang M; Zope M; Perakis AA; Sukhumalchandra P; Philips AV; Garber HR; Kerros C; St John LS; Khouri MR; Khong H; Clise-Dwyer K; Miller LP; Wolpe S; Overwijk WW; Molldrem JJ; Ma Q; Shpall EJ; Mittendorf EA
Clin Cancer Res; 2019 Apr; 25(8):2610-2620. PubMed ID: 30647079
[TBL] [Abstract][Full Text] [Related]
14. Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia.
He H; Kondo Y; Ishiyama K; Alatrash G; Lu S; Cox K; Qiao N; Clise-Dwyer K; St John L; Sukhumalchandra P; Ma Q; Molldrem JJ
Leukemia; 2020 Jun; 34(6):1626-1636. PubMed ID: 31908357
[TBL] [Abstract][Full Text] [Related]
15. WT1, PRAME, and PR3 mRNA Expression in Acute Myeloid Leukemia (AML).
Steger B; Floro L; Amberger DC; Kroell T; Tischer J; Kolb HJ; Schmetzer HM
J Immunother; 2020; 43(6):204-215. PubMed ID: 32502139
[TBL] [Abstract][Full Text] [Related]
16. Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer.
Goldberg J; Qiao N; Guerriero JL; Gross B; Meneksedag Y; Lu YF; Philips AV; Rahman T; Meric-Bernstam F; Roszik J; Chen K; Jeselsohn R; Tolaney SM; Peoples GE; Alatrash G; Mittendorf EA
Cancer Res Commun; 2024 Feb; 4(2):496-504. PubMed ID: 38335301
[TBL] [Abstract][Full Text] [Related]
17. Opportunities and Challenges for Antibodies against Intracellular Antigens.
Yang X; Xie S; Yang X; Cueva JC; Hou X; Tang Z; Yao H; Mo F; Yin S; Liu A; Lu X
Theranostics; 2019; 9(25):7792-7806. PubMed ID: 31695801
[TBL] [Abstract][Full Text] [Related]
18. ANCA-Associated Vasculitides and Hematologic Malignancies: Lessons from the Past and Future Perspectives.
Folci M; Ramponi G; Shiffer D; Zumbo A; Agosti M; Brunetta E
J Immunol Res; 2019; 2019():1732175. PubMed ID: 31198793
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma.
Alatrash G; Perakis AA; Kerros C; Peters HL; Sukhumalchandra P; Zhang M; Jakher H; Zope M; Patenia R; Sergeeva A; Yi S; Young KH; Philips AV; Cernosek AM; Garber HR; Qiao N; Weng J; St John LS; Lu S; Clise-Dwyer K; Mittendorf EA; Ma Q; Molldrem JJ
Clin Cancer Res; 2018 Jul; 24(14):3386-3396. PubMed ID: 29661776
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
